Molbio Diagnostics IPO

About Molbio Diagnostics Company

Molbio Diagnostics, incorporated in October 2000 in Goa, began as a developer of in-vitro diagnostic reagents and has since evolved into a global molecular diagnostics company focused on rapid, point-of-care testing for infectious and select non-communicable diseases. Its core business centers on the proprietary Truenat platform—a portable, battery-operated, real-time PCR system—comprising the Trueprep nucleic-acid extraction device and Truelab analyzer, which delivers accurate results in about an hour and supports a broad menu of assays for tuberculosis, COVID-19, HIV, hepatitis, HPV, and other conditions. Over time, Molbio has expanded beyond molecular diagnostics into adjacent areas such as portable radiology, digital pathology, and breast-health screening through acquisitions and partnerships, while maintaining a strong R&D focus and manufacturing footprint in India. A notable strength is its ability to deploy gold-standard molecular testing in resource-constrained settings, including public health programs, with a large installed base and recurring consumables model. The company serves diagnostic service providers, hospitals, medical colleges, and government programs, and its approach emphasizes affordable, decentralized testing, close collaboration with healthcare stakeholders, and continuous platform innovation to address accessibility and speed-to-result challenges in clinical diagnostics.